RxDoctor Payments Data

James Fulmer, MD

Family Medicine · Greenbrier, ARNPI 1093030918

Payments from drug & device makers

$9,852in general payments, 2019–2025

Across 681 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$856
  • Novo Nordisk$851
  • Pfizer$685
  • Lilly USA, LLC$676
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$9,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,852 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$50,141
Medicare patients
348
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$232,095
MounjaroTirzepatide123$146,465
EliquisApixaban122$100,943
Synjardy XrEmpagliflozin/Metformin Hcl75$71,473
Tresiba Flextouch U-200Insulin Degludec53$58,818
JardianceEmpagliflozin66$53,337
LinzessLinaclotide57$44,970
FarxigaDapagliflozin Propanediol59$40,884
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$38,218
Xigduo XrDapaglifloz Propaned/Metformin35$38,100
VraylarCariprazine Hcl22$31,526
RybelsusSemaglutide19$28,194
XareltoRivaroxaban18$21,320
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$19,215
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$14,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$851$260,289222 claims
Lilly USA, LLCMounjaro$676$146,465123 claims
Boehringer IngelheimSynjardy Xr, Jardiance$241$124,809141 claims
PfizerEliquis, Paxlovid$685$103,760146 claims
AbbVieLinzess, Vraylar$1,547$76,49679 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$856$64,59295 claims
GSKTrelegy Ellipta$1,025$38,21842 claims
Johnson & JohnsonXarelto$285$21,32018 claims
MerckBelsomra, Januvia$314$19,88331 claims
Astellas Pharma US IncMyrbetriq$84$12,60917 claims
Antares Pharma, Inc.Xyosted$198$7,88013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Greenbrier

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →